Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PAXIL CR vs CELEXA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Paroxetine is a selective serotonin reuptake inhibitor (SSRI). It potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane, resulting in increased serotonin concentrations in the synaptic cleft.
Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity in the CNS by blocking reuptake of serotonin into presynaptic neurons.
Major depressive disorder,Obsessive-compulsive disorder,Panic disorder,Social anxiety disorder,Generalized anxiety disorder,Posttraumatic stress disorder,Premenstrual dysphoric disorder (off-label),Hot flashes (off-label)
Major depressive disorder,Obsessive-compulsive disorder,Panic disorder,Social anxiety disorder,Generalized anxiety disorder,Post-traumatic stress disorder,Premenstrual dysphoric disorder
12.5-37.5 mg orally once daily in the morning; initial dose 12.5 mg/day, titrate by 12.5 mg/day at intervals of at least 1 week to maximum 50 mg/day.
20 mg orally once daily initially, may increase to 40 mg once daily after at least 1 week; maximum 40 mg/day.
The terminal elimination half-life of paroxetine (PAXIL CR) is approximately 15-20 hours. This supports once-daily dosing and requires about 5-7 days to reach steady-state concentration.
Terminal elimination half-life is approximately 35 hours (range 23–45 h) in healthy adults. This long half-life allows once-daily dosing; steady state is reached in about 1 week. In elderly patients, half-life may extend to 45–90 hours.
Extensively metabolized in the liver primarily via cytochrome P450 enzyme CYP2D6. Paroxetine is a potent inhibitor of CYP2D6. Metabolites are less active and are excreted in urine and feces.
Hepatic via CYP2C19 (major), CYP3A4, and CYP2D6; active metabolites: S-demethylcitalopram and didemethylcitalopram.
Renal excretion accounts for approximately 64% of the administered dose, with 2% as unchanged parent drug and the remainder as metabolites. Fecal excretion accounts for about 36%, mostly as metabolites. Less than 1% is excreted in bile.
Primarily renal: 75% as metabolites (10% as parent citalopram, 65% as desmethylcitalopram, didesmethylcitalopram, and citalopram-N-oxide). Fecal excretion accounts for approximately 20% of the dose. Biliary excretion minimal.
Approximately 93-95% bound to plasma proteins, primarily alpha-1-acid glycoprotein and albumin.
Approximately 80% bound to plasma proteins (primarily albumin and α1-acid glycoprotein). Binding is independent of drug concentration.
Apparent volume of distribution (Vd/F) is approximately 3-28 L/kg, with an average of about 13 L/kg. This wide distribution indicates extensive tissue partitioning, with brain concentrations several times higher than plasma.
Mean Vd is 12 L/kg (range 8–16 L/kg). This large Vd indicates extensive extravascular distribution, including CNS penetration. High Vd contributes to the long half-life.
Oral bioavailability of PAXIL CR is about 30% due to first-pass metabolism, but is lower than the immediate-release formulation (50%). Food does not significantly affect bioavailability.
Oral bioavailability is approximately 80% (range 60–90%). No significant first-pass metabolism. Food does not affect bioavailability.
Creatinine clearance 30-60 m L/min: use lower end of dosing range (12.5 mg/day maximum). Creatinine clearance <30 m L/min: not recommended.
GFR >20 m L/min: no adjustment; GFR ≤20 m L/min: maximum 20 mg/day; not recommended for GFR <10 m L/min.
Child-Pugh Class A or B: initial dose 12.5 mg/day, maximum 25 mg/day. Child-Pugh Class C: not recommended.
Child-Pugh Class A: 10 mg once daily; Child-Pugh Class B or C: maximum 20 mg/day with careful titration.
Not approved for use in pediatric patients; safety and efficacy not established.
Adolescents 12-17 years: 10 mg orally once daily initially, may increase to 20 mg once daily after 3 weeks; maximum 20 mg/day. Children <12 years: not approved.
Initial dose 12.5 mg/day; maximum 25 mg/day. Increased sensitivity to serotonin reuptake inhibition; monitor for hyponatremia and QT prolongation.
Patients >60 years: 10 mg orally once daily initially, maximum 20 mg once daily.
Suicidality and Antidepressant Drugs: Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults in short-term trials. Monitor closely for clinical worsening, suicidality, or unusual changes in behavior.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Clinical worsening and suicide risk,Serotonin syndrome,Bleeding abnormalities,Activation of mania/hypomania,Seizures,Angle-closure glaucoma,Hyponatremia,Bone fractures,Discontinuation syndrome (withdrawal reactions)
QT prolongation, serotonin syndrome, hyponatremia, increased risk of bleeding, activation of mania/hypomania, seizures, angle-closure glaucoma, sexual dysfunction, and discontinuation syndrome.
Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI,Concomitant use with pimozide or thioridazine,Known hypersensitivity to paroxetine or any component of the formulation
Concomitant use with MAOIs or within 14 days of MAOI use, concomitant use with pimozide, hypersensitivity to citalopram or any excipients.
No specific food restrictions, but avoid excessive alcohol intake. Grapefruit has not been reported to interact significantly with paroxetine.
No specific food interactions. Avoid grapefruit and grapefruit juice as they may increase citalopram levels via CYP3A4 inhibition. Alcohol may exacerbate CNS depression and should be avoided.
First trimester: Increased risk of congenital cardiovascular malformations (primarily septal defects) and persistent pulmonary hypertension of the newborn (PPHN). Third trimester: Risk of neonatal adaptation syndrome (irritability, feeding difficulties, respiratory distress) and prolonged QT interval. Late third trimester exposure may cause serotonin syndrome in neonate.
First trimester: Data insufficient to definitively assess major malformation risk; some studies suggest small increased risk of cardiac defects (e.g., septal defects). Second/Third trimester: Risk of persistent pulmonary hypertension of the newborn (PPHN), preterm birth, low birth weight; late third trimester exposure may cause neonatal adaptation syndrome (irritability, respiratory distress, feeding difficulties).
Paroxetine is excreted into breast milk. M/P ratio is approximately 0.39. Milk levels vary; peak concentration occurs 2-4 hours post-dose. Most studies show no adverse effects in breastfed infants, but cases of irritability, poor feeding, and transient serotonin-like symptoms have been reported. Use caution; monitor infant for drowsiness, restlessness, and weight gain.
Citalopram is excreted into breast milk; average infant dose relative to maternal weight-adjusted dose is 3.9% (range 1.7-8.5%). Milk-to-plasma ratio (M/P) approximately 1.5. Cases of adverse effects in breastfed infants (excessive somnolence, poor feeding) reported; caution with higher maternal doses. Benefits of breastfeeding generally outweigh risks for mild cases, but alternative agents with lower M/P (e.g., sertraline, paroxetine) may be preferred for moderate-severe depression.
Paroxetine clearance may decrease in pregnancy, leading to higher plasma concentrations. However, dose adjustments are generally not routinely recommended due to limited data. Consider therapeutic drug monitoring if response is inadequate or side effects occur. The risk of birth defects with high doses (>30 mg/day) may be increased, so use lowest effective dose (12.5-37.5 mg/day CR). Avoid abrupt discontinuation; taper slowly postpartum.
Pregnancy may reduce citalopram plasma concentrations by 30-50% due to increased volume of distribution and enhanced hepatic clearance (CYP2C19 induction). Dose adjustment should be guided by clinical response (depressive symptom monitoring) and trough serum concentrations if available. A 30-50% dose increase (e.g., from 20 mg to 30-40 mg) may be needed, especially in third trimester. Postpartum: Dose should be tapered back to pre-pregnancy levels within 1–2 weeks to avoid toxicity.
PAXIL CR (paroxetine extended-release) has a longer half-life than immediate-release, allowing once-daily dosing but requiring 3-4 weeks for steady state. Due to its potent CYP2D6 inhibition, use caution with tamoxifen (reduces active metabolite) and with other serotonergic drugs (risk of serotonin syndrome). Discontinuation syndrome is common; taper gradually. Pregnancy category D; avoid in third trimester due to risk of persistent pulmonary hypertension of the newborn (PPHN).
Celexa (citalopram) is an SSRI antidepressant. Key pearls: (1) Max dose 40 mg/day due to QT prolongation risk at higher doses; (2) CYP2C19 and CYP3A4 metabolism; avoid with MAOIs and linezolid; (3) Onset of therapeutic effect takes 2-4 weeks; (4) More selective for serotonin reuptake than fluoxetine or paroxetine, with fewer drug interactions; (5) May cause mild SIADH in elderly; (6) Abrupt discontinuation can cause withdrawal syndrome; (7) Electrolyte monitoring recommended in patients at risk for QT prolongation.
Take this medication once daily, usually in the morning with or without food. Swallow the tablet whole; do not crush, chew, or divide.,It may take several weeks to feel the full benefit; do not stop suddenly as withdrawal symptoms may occur.,Avoid alcohol while taking PAXIL CR as it can increase dizziness and drowsiness.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Report any suicidal thoughts or unusual changes in mood immediately.,Do not take with MAO inhibitors (e.g., phenelzine) or within 14 days of stopping them.,Contact a healthcare professional if you experience symptoms of serotonin syndrome (fever, muscle stiffness, confusion, rapid heart rate).
Take exactly as prescribed; do not increase dose without consulting your doctor.,It may take 2-4 weeks to feel the full benefit; do not stop abruptly.,Avoid alcohol while taking this medication.,Report any symptoms of serotonin syndrome (agitation, hallucinations, rapid heart rate, fever, muscle stiffness) immediately.,Notify your doctor if you experience unusual bleeding or bruising, or if you have a history of QT prolongation or electrolyte disturbances.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PAXIL CR vs CELEXA, answered by our medical review team.
PAXIL CR is a SSRI Antidepressant that works by Paroxetine is a selective serotonin reuptake inhibitor (SSRI). It potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane, resulting in increased serotonin concentrations in the synaptic cleft.. CELEXA is a SSRI Antidepressant that works by Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity in the CNS by blocking reuptake of serotonin into presynaptic neurons.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PAXIL CR and CELEXA depend on the specific clinical indication. These are both SSRI Antidepressant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PAXIL CR is: 12.5-37.5 mg orally once daily in the morning; initial dose 12.5 mg/day, titrate by 12.5 mg/day at intervals of at least 1 week to maximum 50 mg/day.. The standard adult dose of CELEXA is: 20 mg orally once daily initially, may increase to 40 mg once daily after at least 1 week; maximum 40 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PAXIL CR and CELEXA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PAXIL CR is classified as Category C. First trimester: Increased risk of congenital cardiovascular malformations (primarily septal defects) and persistent pulmonary hypertension of the newborn (PPHN). Third trimester: . CELEXA is classified as Category C. First trimester: Data insufficient to definitively assess major malformation risk; some studies suggest small increased risk of cardiac defects (e.g., septal defects). Second/Third. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.